CalciMedica, Inc.
$0.66
▼
-0.54%
2026-04-21 05:52:01
calcimedica.com
NCM: CALC
Explore CalciMedica, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.49 M
Current Price
$0.66
52W High / Low
$7.2 / $0.46
Stock P/E
—
Book Value
$-0.43
Dividend Yield
—
ROCE
-235.71%
ROE
-7.61%
Face Value
—
EPS
$-1.87
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
1.09
Debt / Equity
-1.46
Current Ratio
3.58
Quick Ratio
3.58
Forward P/E
-0.38
Price / Sales
—
Enterprise Value
$6.41 M
EV / EBITDA
-0.28
EV / Revenue
—
Rating
None
Target Price
$10.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Anixa Biosciences, Inc. | $3 | — | $100.58 M | — | -82.91% | -68.06% | $5.46 / $2.44 | $0.45 |
| 2. | Crescent Biopharma, Inc. | $21.69 | — | $575.8 M | — | -74.74% | -1.61% | $29 / $8.72 | $5.99 |
| 3. | OS Therapies Incorporated | $1.38 | — | $58.43 M | — | 582.87% | 614.26% | $2.57 / $1.15 | $-0.16 |
| 4. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 5. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 6. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 7. | Aptevo Therapeutics Inc. | $5.21 | — | $6.24 M | — | -124.44% | -2.35% | $486 / $3.8 | $17.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.38 M | -5.62 M | -6.62 M | -6.5 M | -6.17 M | — |
| Net Profit | -10.76 M | -7.8 M | -5.96 M | -5.04 M | -4.26 M | — |
| EPS in Rs | -0.68 | -0.5 | -0.38 | -0.32 | -0.27 | -0.5 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -23.12 M | -24.2 M | -38.08 M | -14.19 M |
| Net Profit | -29.56 M | -13.7 M | -34.36 M | -7.82 M |
| EPS in Rs | -1.88 | -0.87 | -2.18 | -0.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 13.59 M | 19.79 M | 12.19 M | 3.35 M |
| Total Liabilities | 20.23 M | 5.38 M | 4.03 M | 12.58 M |
| Equity | -6.64 M | 14.41 M | 8.16 M | -9.23 M |
| Current Assets | 13.53 M | 19.66 M | 11.61 M | 1.73 M |
| Current Liabilities | 3.78 M | 3.68 M | 4.03 M | 4.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -21.18 M | -21.15 M | -25.73 M | -11.76 M |
| Investing CF | 9.55 M | -4.42 M | 8.88 M | -0 M |
| Financing CF | 15.21 M | 27.97 M | 20.9 M | 8.48 M |
| Free CF | -21.21 M | -21.15 M | -25.81 M | -11.76 M |
| Capex | -0.03 M | -0.01 M | -0.08 M | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 60.12% | -339.12% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.